Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2007, the company has established itself as a leader in developing innovative injectable products, particularly in the areas of oncology and critical care. With a focus on improving patient outcomes, Eagle Pharmaceuticals offers unique formulations that enhance the delivery and efficacy of established therapies. The company has achieved significant milestones, including the successful launch of its flagship product, Ryanodex, which is designed for the treatment of malignant hyperthermia. Eagle's commitment to quality and innovation has positioned it favourably in a competitive market, earning recognition for its contributions to patient care and drug accessibility. With operations extending across major regions in the US, Eagle Pharmaceuticals continues to drive advancements in the biopharmaceutical landscape.
DitchCarbon Score
How does Eagle Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eagle Pharmaceuticals, Inc.'s score of 25 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Eagle Pharmaceuticals, Inc.'s reported carbon emissions
Eagle Pharmaceuticals, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As of now, Eagle Pharmaceuticals has not established any science-based targets or commitments to reduce emissions, nor does it inherit any emissions data from a parent company. This lack of publicly available information suggests that the company may still be in the early stages of developing its climate strategy and emissions reporting framework. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and carbon reduction initiatives. However, without specific commitments or data, it is challenging to assess Eagle Pharmaceuticals' position relative to its peers in terms of climate action.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eagle Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
